<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987268</url>
  </required_header>
  <id_info>
    <org_study_id>CHIP RETENTION V1.0</org_study_id>
    <nct_id>NCT04987268</nct_id>
  </id_info>
  <brief_title>CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation</brief_title>
  <acronym>CHIP-RETENTION</acronym>
  <official_title>Clonal Hematopoiesis of Indeterminate Potential and Residual Cardiovascular Event Tendency After Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Northern Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to identify the association between clonal hematopoiesis of indeterminate potential&#xD;
      (CHIP) and cardiovascular risks after smoking cessation, this study intends to recruit ACS&#xD;
      patients undergoing complete revascularization and perform whole-exome sequencing for&#xD;
      enrolled patients to identify the prevalence of CHIP mutations. After 1-year follow-up, the&#xD;
      relationship of presence of CHIP mutations and the occurrence of MACCEs will be explored,&#xD;
      irrespective of smoking cessation or not. CHIP may be a potential risk factor of poor&#xD;
      prognosis of ACS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2021</start_date>
  <completion_date type="Anticipated">August 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>prevalence of CHIP mutations</measure>
    <time_frame>24 hours</time_frame>
    <description>Whole-exome sequencing is performed to detect the presence of CHIP mutations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>1 year</time_frame>
    <description>MACCE includes cardiac death, non-fatal MI, non-fatal stroke, rehospitalization due to heart failure, ischemia-driven revascularization at 12 months</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1029</enrollment>
  <condition>ACS</condition>
  <condition>Clonal Hematopoiesis of Indeterminate Potential</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Current-smoking</arm_group_label>
    <description>exposure: smoking</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Smoking-cessation</arm_group_label>
    <description>exposure: smoking cessation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-smoking</arm_group_label>
    <description>exposure: none</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>clonal hematopoiesis of indeterminate potential</intervention_name>
    <description>Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)</description>
    <arm_group_label>Current-smoking</arm_group_label>
    <arm_group_label>Smoking-cessation</arm_group_label>
    <arm_group_label>non-smoking</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ACS patients undergoing complete revascularization&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. In-patients with acute coronary syndrome to undergo PCI 2. Complete&#xD;
             revascularization during the index hospitalization 3. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Periprocedural complications (coronary artery dissection, perforation, myocardial&#xD;
             infarction, stroke, death) 2. Planned coronary revascularization at discharge 3.&#xD;
             Patients with severe chronic disease (uremia, liver cirrhosis, COPD (chronic&#xD;
             obstructive pulmonary disease) 4. Abnormal blood counts caused by hematological&#xD;
             diseases 5. Diagnosed malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaling Han, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The General Hospital of Northern Theater Command</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Li, MD</last_name>
    <phone>13352452889</phone>
    <email>lijing790126@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenyang Northern Hospital</investigator_affiliation>
    <investigator_full_name>Han Yaling</investigator_full_name>
    <investigator_title>Director of cardiology, Shenyang Northern Hospital</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

